All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1200+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

Biogen buys access to Neomorph’s molecular glue degrader platform for up to $1.45B
Small molecule, Alzheimer’s, autoimmune, drug discovery, molecular glue degraders - Read more 

THE GOOD
Clinical Trials

Roche posts promising interim Ph1b/2a data for trontinemab in clearing amyloid plaque, despite one patient death
Bispecific antibody, Alzheimer’s disease - Read more

Lexeo Therapeutics posts positive interim Ph1 data for Alzheimer’s disease gene therapy hopeful LX1001
Gene therapy, Alzheimer’s disease, AAV - Read more

CalciMedica touts positive Ph2b data for small molecule Auxora in acute pancreatitis
Small molecule, acute pancreatitis - Read more

Soal Therapeutics’ positive topline Ph2 results for SL-1002 in limb spasticity
Small molecule, limb spasticity - Read more

Amplia Therapeutics posts “excit[ing]” interim Ph2a data for narmafotinib in pancreatic cancer
Small molecule, pancreatic cancer - Read more

Cognition Therapeutics posts pre-specific analysis of Ph2 data for CT1812 in Alzheimer’s disease
Small molecule, Alzheimer’s disease - Read more

Sobi touts pooled Ph3 analysis data for mAb emapalumab in two rare autoinflammatory conditions
Monoclonal antibody, systemic juvenile idiopathic arthritis, adult-onset still's disease - Read more

reMYND showcases positive Ph2a data for REM0046127 in Alzheimer’s disease
Small molecule, Alzheimer’s disease - Read more

THE GOOD
Company Launches

Archon Biosciences launches with $20M seed, drug discovery in new class of therapeutics dubbed “antibody cages”
Antibody cages, drug discovery, AI - Read more

THE GOOD
Earnings & Finances

AbbVie lifts full year profit guidance as Skyrizi sales soar to new heights
Monoclonal antibody, plaque psoriasis, psoriatic arthritis, Crohn's disease - Read more

Incyte’s pins hopes on three upcoming launches to solve their upcoming patent cliff woes
Monoclonal antibody, cancer - Read more

Biogen raises guidance on after strong performance, even from controversial Alzheimer’s med Leqembi
Monoclonal antibody, Alzheimer’s disease - Read more

BioMarin’s earnings shoot past estimates, driven by rare genetic disease therapy growth
Small molecule, achondroplasia, gene therapy, hemophilia A - Read more

PRESENTED BY YOU?
Get the attention of 1200+ Biotech & Pharma Professionals 🤩

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here!

If you want to see our prospectus or if you’re ready to work with us, just reply to this email or message me on LinkedIn.

⬇️ More Good News ⬇️

THE GOOD
Fundraises

Axonis $115M Series A, small molecules for neurological disorders
Small molecule, pain, epilepsy - Read more

Blue Earth Therapeutics $76.5M Series A for next-gen radioligand therapies
Radiopharm, prostrate cancer, radioligand - Read more

TXN Systems SEK25M ($2.3M) Series A, develop antibiotics for multi-drug resistant UTIs
Small molecule, urinary tract infection, multi-drug resistant infection - Read more

Leal Therapeutics $45M financing, ALS and schizophrenia therapies
Antisense oligonucleotide, amyotrophic lateral sclerosis, small molecule, schizophrenia - Read more

SynOx Therapeutics adds $17M to top-up their Series B for mAb treating tenosynovial giant cell tumours
Monoclonal antibody, tenosynovial giant cell tumour - Read more

Vaxinano €6M ($6.5M) raise, nasal vaccines
Vaccines, infectious disease, nasal vaccines - Read more

Vara $8.9M raise for AI-powered breast cancer detection
Breast cancer detection, AI - Read more

Experic undisclosed growth investment
CDMO, manufacturing - Read more

THE GOOD
Partnerships

Servier, Aitia expand partnership, leveraging AI, digital twins for glioma drug discovery
Drug discovery, glioma, cancer, AI, digital twin - Read more

SandboxAQ, The Michael J. Fox Foundation partner on developing novel Parkinson’s disease therapies
Drug development, Parkinson’s disease - Read more

Biond Biologics, Merck KGaA clinical trial collab for BND-35 + cetuximab in solid tumor-targeting Ph1
Monoclonal antibody, solid tumor, cancer - Read more

Insilico Medicine, Sanofi announce AI-facilitated lead identification as part of drug discovery partnership
Drug discovery, cancer, AI - Read more

Catalent, IsomAb strategic collaboration, cell line development
Antibody, type 2 diabetes, peripheral artery disease, process development - Read more

THE GOOD
Patient Access

Novo Nordisk looks to have quelled Ozempic, Wegovy shortages, though patients may still experience “variability” in access
GLP-1, obesity, type 2 diabetes - Read more

THE GOOD
Research

3D tumor renderings provide fresh insights into tumor growth
3D rendering, tumor growth, cancer - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Earnings & Finances

Eli Lilly’s obesity money-makers disappoint investors as quarter-over-quarter sales growth didn’t happen
GLP-1, obesity, type diabetes - Read more

GSK earnings a dud as RSV, shingles shot sales sputter
Vaccine, respiratory syncytial virus, shingles - Read more

THE BAD
Layoffs

Spero Therapeutics cuts 39% of staff after antibiotic disappointment
Small molecule, nontuberculous mycobacterial pulmonary disease, antibiotic - Read more

Walgreens continues cost-cutting tirade with 256 slashed support centre roles
Pharmacy, healthcare, retail - Read more

THE BAD
Strategic Plans

Eli Lilly’s $2.4B Dice Therapeutics gamble not looking so hot after lead program (DC-806) development cut
Small molecule, psoriasis - Read more

GSK also cuts development of an asset from a billion dollar+ acquisition, pneumococcal vaccine from $2.1B Affinivax takeover
Vaccine, pneumococcal disease - Read more

THE UGLY
Criminal Acts

AstraZeneca’s China operations president under investigation by Chinese authorities; reasons for investigation undisclosed - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here